The novel coronavirus, referred to as SARS-COV 2, originated in Wuhan, China in December 2019. Since many Health Care Workers (HCW) and general public lost their lives. The only thing which can prevent from being infected is social distancing and wearing of mask (N95) and wearing of mask has its own adverse effects. This is a retrospective study conducted in the
Otorhinolaryngological manifestations are common among patients suffering from COVID-19. This study provides a brief and precise review of the current knowledge regarding COVID-19 including disease transmission and clinical characteristics. This article aims to review the otolaryngologist experience treating patients in the cities where COVID 19 impact is most, and to propose appropriate protective measures while managing ENT patients. This is a retrospective study conducted in the Department of Otorhinolaryngology, Hind Institute of Medical Sciences, Ataria, Sitapur from 10 March 2020 to 4 May 2020. The most common otolaryngological symptoms of COVID-19 were cough, sore throat, and dyspnea. Rhinorrhea, nasal congestion and dizziness also seen in some of the patients. COVID-19 could also manifest as an isolated sudden hyposmia/anosmia. Upper respiratory tract (URT) symptoms were commonly observed in younger patients and usually appeared initially. They could be present even before the molecular confirmation of SARS-CoV-2. Otolaryngologists are at higher risk for SARS-CoV-2 infection as they cope with URT symptoms in OPD and while performing surgery in COVID-19 positive patients. Patients with cough, sore throat, dyspnea, hyposmia/anosmia and a history of travel to the region with confirmed COVID-19 patients, should be considered as potential COVID-19 cases. An otolaryngologist should wear FFP3/N95 mask, glasses, disposable and fluid resistant gloves and gown while examining such individuals. ENT surgeries should be postponed if not urgent.
<bold>Introduction:</bold> Chemoradiation is an important component in the management of Head and Neck Cancers, which has hearing loss as a major adverse effect. This is due to the inclusion of ear structures in the radiation field and Cisplatin, an anti-neoplastic drug which can cause ototoxicity. The role of audiological screening in the form of Pure Tone Audiometry & Distortion Product Otoacoustic Emissions is hereby studied in these patients. <bold>Material and Methods:</bold> The present study was undertaken to highlight the effects of concurrent chemoradiation on the audiological profile of Head and Neck Cancer patients. The patients underwent pre-treatment and post treatment Pure Tone Audiometry and Distortion Product Otoacoustic Emission. The results were statistically analysed. <bold>Results:</bold> 36 patients who underwent concurrent chemoradiation for Head and Neck Cancers were enrolled. Post treatment PTA values were significantly different from Pre-treatment values especially at 500Hz. DPOAEs also indicated significant changes in cochleotoxicity grading after concurrent chemoradiation. <bold>Conclusion:</bold> Concurrent Chemoradiation exerts a significant effect on hearing status of the patients. Simple screening tests like DPOAE can detect cochlear damage prior to detection with Pure Tone Audiometry. Addition of these tests is recommended as routine screening during Concurrent Chemoradiation.
Introduction: Oral cancer is the term referred to oral squamous cell carcinoma of the oral mucosa as it forms 95% of oral cancer cases. It is estimated to be the sixth most common cancer which accounts for 0.6% to 5% of all cancers. Neck metastasis is one of the most important factor determining the progress.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.